Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 2.3% Higher

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s share price traded up 2.3% during mid-day trading on Monday . The stock traded as high as $7.56 and last traded at $7.49. 792,935 shares traded hands during trading, a decline of 87% from the average session volume of 6,186,341 shares. The stock had previously closed at $7.32.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $17.00 target price on shares of Recursion Pharmaceuticals in a research report on Tuesday, June 25th.

Recursion Pharmaceuticals Trading Down 2.8 %

The firm has a fifty day moving average of $8.77 and a two-hundred day moving average of $9.83. The company has a market cap of $1.72 billion, a PE ratio of -4.52 and a beta of 0.83.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.04. Recursion Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 765.90%. The company had revenue of $13.80 million during the quarter, compared to analyst estimates of $11.10 million. During the same quarter last year, the firm posted ($0.34) EPS. The firm’s revenue for the quarter was up 14.0% on a year-over-year basis. Sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -1.56 EPS for the current fiscal year.

Insiders Place Their Bets

In other Recursion Pharmaceuticals news, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction dated Thursday, June 27th. The stock was sold at an average price of $7.21, for a total value of $43,260.00. Following the completion of the transaction, the chief operating officer now owns 535,457 shares in the company, valued at approximately $3,860,644.97. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Recursion Pharmaceuticals news, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction dated Thursday, June 27th. The stock was sold at an average price of $7.21, for a total value of $43,260.00. Following the completion of the transaction, the chief operating officer now owns 535,457 shares in the company, valued at approximately $3,860,644.97. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Michael Secora sold 23,124 shares of the firm’s stock in a transaction dated Wednesday, April 17th. The stock was sold at an average price of $7.58, for a total value of $175,279.92. Following the completion of the transaction, the chief financial officer now owns 1,231,055 shares of the company’s stock, valued at approximately $9,331,396.90. The disclosure for this sale can be found here. Insiders sold a total of 207,359 shares of company stock worth $1,704,435 in the last quarter. 15.75% of the stock is owned by company insiders.

Institutional Trading of Recursion Pharmaceuticals

Large investors have recently modified their holdings of the business. Benjamin F. Edwards & Company Inc. bought a new stake in shares of Recursion Pharmaceuticals during the 1st quarter valued at about $26,000. National Bank of Canada FI boosted its position in shares of Recursion Pharmaceuticals by 90.9% during the 4th quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock valued at $31,000 after acquiring an additional 1,500 shares during the last quarter. First Horizon Advisors Inc. bought a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at about $47,000. GAMMA Investing LLC lifted its position in Recursion Pharmaceuticals by 1,588.4% in the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after buying an additional 6,036 shares during the last quarter. Finally, Oxford Wealth Group LLC bought a new stake in Recursion Pharmaceuticals in the 1st quarter worth approximately $106,000. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.